The FDA has granted orphan drug designation to Boehringer Ingelheim’s anti-CD33 monoclonal antibody BI 836858 for the treatment of myelodysplastic syndromes (MDS).

MDS are a group of bone marrow disorders. The bone marrow produces blood cells. In MDS, the bone marrow is characterized by cell abnormalities and ineffective blood cell production. Various subtypes of the disease exist with variable prognoses and treatment options.